Scott P Perlman

December 18, 2015 | Corporate Counsel

In the past five years since the adoption of the Affordable Care Act, the health care industry has experienced an unprecedented wave of consolidation and collaboration. While these collaborations offer potential “procompetitive” benefits, such as lower rates and premiums for health plans, employers and patients, they also can raise antitrust concerns.

By Scott P. Perlman

7 minute read

December 17, 2015 | Corporate Counsel

In the past five years since the adoption of the Affordable Care Act, the health care industry has experienced an unprecedented wave of consolidation and collaboration. While these collaborations offer potential “procompetitive” benefits, such as lower rates and premiums for health plans, employers and patients, they also can raise antitrust concerns.

By Scott P. Perlman

7 minute read

December 05, 2002 | Law.com

Since the late 1990s, U.S. antitrust enforcement authorities have greatly increased their scrutiny of the potential anti-competitive effects of patent settlements. The FTC has taken the lead in charting the course between permissible and unlawful patent settlement agreements in a series of enforcement actions involving pharmaceuticals.

By Scott P. Perlman and Jay S. Brown

12 minute read